Serum concentration of homocysteine and the risk of atherosclerosis in patients with obstructive sleep apnea syndrome
Kumor, M.; Rubinsztajn, R.; Byśkiniewicz, K.; Bielicki, P.; Chazan, R.
Pneumonologia i Alergologia Polska 74(1): 117-121
2006
ISSN/ISBN: 0867-7077 PMID: 17175990 Document Number: 600210
to evaluate usefulness of serum homocysteine concentration in assessing the risk of atherosclerosis in patients with OSAS. 47 patients (mean age 50.6+/-10.3 years, mean BMI 31.52+/-6.04 kg/m2), with OSAS confirmed by polisomnography and 12 healthy snoring subjects (mean age 42.8 +/-16.8 years, mean BMI 26.9+/-2.95 kg/m2) were enrolled to the study. OSAS patients were divided into two groups - subjects with normal blood pressure (group A, n=32, mean age 51.3+/-10.3 years, mean BMI 30.6+/-4.4 kg/m2) and subjects with arterial hypertension (group B, n=15, mean age 52.7+/-9.8 years, mean BMI 31.4+/-5.0 kg/m2). None of the study subjects was treated with statins or fibrates. Serum concentration ofhomocysteine, uric acid, glucose level and lipid profile was evaluated in all subjects. We found significant abnormalities in the lipid profile in all the study groups. The mean concentrations of cholesterol (mg/dL), triglycerides (mg/dL) and homocysteine (micromol/L) were as follows: 215.0+/-34.2, 200.0+/-173.0, 8.2+/-2.9 in group A, 216.5+/-43.1, 189.3+/-138.8, 8.40+/-1.67 in group B. 195.0+/-32.9, 154.3+/-133.0, 9.3+/-2.1 in the control group. No significant correlation between the homocysteine concentration and level of cholesterol or triglycerides was found. the serum concentration of homocysteine seems not to be a good marker in the evaluation of the risk of atherosclerosis in patients with OSAS.